Amarin: Is It Time to Test the Waters?
Amarin (NASDAQ:AMRN) released better-than-expected 2019 fourth-quarter results after the closing bell Tuesday. The biopharma's stock promptly dropped by another 0.86%, bringing its total loss for the year to a disappointing 18.4%.
What's behind this relentless downward trend? Well, first off, most stocks are getting hammered right now due to the confluence of the COVID-19 illness, worries about the possible impact of a Bernie Sanders presidency on the pharmaceutical and banking industries, and the simple fact that most equities were flat-out overvalued from a historical perspective. Amarin hasn't been able to escape this vortex of headwinds during the opening weeks of 2020.
Image source: Getty Images.
Source Fool.com
